

- H. B. Lassman, and J. C. Wilker, *J. Med. Chem.*, **20**, 66 (1977); (b) D. E. Aultz, A. R. McFadden, and H. B. Lassman, *ibid.*, **20**, 456 (1977).
- (3) H. Tagawa and K. Ueno, *Chem. Pharm. Bull.*, in press.
- (4) A. Allais, G. Rousseau, J. Meier, R. Deraedt, J. Benzoni, and L. Chiffot, *Eur. J. Med. Chem.*, **9**, 381 (1974).
- (5) A. Andreani, D. Bonazzi, M. Rambaldi, A. Guarneri, F. Andreani, P. Strocchi, and N. Montanaro, *J. Med. Chem.*, **20**, 1344 (1977).
- (6) I. T. Harrison, B. Lewis, P. Nelson, W. Rooks, A. Roszkowski, A. Tomolonis, and H. J. Fried, *J. Med. Chem.*, **13**,

- 203 (1970).
- (7) Beecham Group Ltd., British Patent 1474377 (May 25, 1977).
- (8) SIR Laboratori Chimico Biologici SPA, British Patent 1383465 (Feb 12, 1975).
- (9) E. C. Fieller, *J. R. Stat. S.*, **7** (Suppl.), 1 (1940).
- (10) J. T. Litchfield, Jr., and F. Wilcoxon, *J. Pharmacol. Exp. Ther.*, **96**, 99 (1949).
- (11) K. Stach and H. Spingler, *Angew. Chem.*, **74**, 31 (1962).
- (12) H. Perkin, Jr., J. Frederic, and S. Stone, *J. Chem. Soc.*, **127**, 2275 (1925).


Folate Antagonists. 12. Antimalarial and Antibacterial Effects of 2,4-Diamino-6-[(aralkyl and alicyclic)thio-, sulfinyl-, and sulfonyl]quinazolines^{1,2}

Edward F. Elslager, John Davoll, Patricia Jacob, A. M. Johnson, Judith Johnson, and Leslie M. Werbel*


Chemistry Departments, Warner-Lambert/Parke-Davis Pharmaceutical Research Division, Ann Arbor, Michigan 48106, and Parke-Davis and Company, Pontypool, United Kingdom. Received September 23, 1977

A series of 2,4-diamino-6-[(aralkyl and alicyclic)thio-, sulfinyl-, and sulfonyl]quinazolines was prepared via condensation of 5-chloro-2-nitrobenzonitrile or 5,6-dichloro-2-nitrobenzonitrile with the appropriate aralkyl or alicyclic thiopseudourea, reduction of the resulting 2-nitro-5-[(aralkyl or alicyclic)thio]benzonitrile with stannous chloride to the amine, and cyclization with chloroformamidine hydrochloride. Oxidation was effected with hydrogen peroxide or the bromine complex of 1,4-diazabicyclo[2.2.2]octane. These analogues when examined for suppressive activity against drug-sensitive lines of *Plasmodium berghei* in mice were not as active as 2,4-diamino-6-[(3,4-dichlorobenzyl)amino]quinazoline (Ia).


Many 2,4-diaminoquinazoline antifolates have been demonstrated to possess strong antimalarial properties against sensitive and drug-resistant lines of *Plasmodium berghei* in mice, *P. gallinaceum* in chicks, and *P. cynomolgi* and *P. knowlesi* in rhesus monkeys.^{3,4} Among the most potent are 2,4-diamino-6-[(3,4-dichlorobenzyl)amino]quinazoline (Ia), 2,4-diamino-6-[(3,4-dichlorobenzyl)-



nitrosoamino]quinazoline (Ib), and 2,4-diamino-6-[(3,4-dichlorobenzyl)methylamino]quinazoline (Ic).^{1,3-6} However, antimalarial activity of oxygen bioisosteres, exemplified by 2,4-diamino-6-[(p-chlorobenzyl)oxy]quinazoline (II), was greatly reduced.⁷ Interestingly, extrusion of the




methylene bridge of II restored antimalarial activity. Thus 2,4-diamino-6-(p-chlorophenoxy)quinazoline (IIIa) and



2,4-diamino-6-(3,4-dichlorophenoxy)quinazoline (IIIb)

Scheme I





exhibited oral antimalarial effects against *P. berghei* in mice comparable with or superior to 2,4-diamino-6-[(3,4-dichlorobenzyl)amino]quinazoline (Ia).⁷ Comparison of the above diaminoquinazoline antifolates with representative thio bioisosteres would therefore be of interest, and we now describe the preparation and biological activities of some 2,4-diamino-6-[(aralkyl and alicyclic)thio-, sulfinyl-, and sulfonyl]quinazolines.

Results and Discussion


Chemistry. The 2,4-diamino-6-[(aralkyl and alicyclic)thio-, sulfinyl-, and sulfonyl]quinazolines were synthesized following the route depicted in Scheme I. Condensation of 5-chloro-2-nitrobenzonitrile (Va) or

Table I. 2-Nitro-5-[(aralkyl and alicyclic)thio]benzonitriles

|  | | | | | | | |
|---|---|----|-----------|-------------------|--------------------------------|-----------|--|
| No. | R | Z | Mp, °C | Yield purified, % | Purification solvent | Procedure | Formula ^a |
| 1 | <i>c</i> -C ₆ H ₁₁ | H | 84-85 | 38 | C ₆ H ₁₂ | I | C ₁₃ H ₁₄ N ₂ O ₂ S |
| 2 | -CH ₂ -C ₆ H ₄ - <i>p</i> -Cl | Cl | 145-146 | 27 | EtOH | II | C ₁₄ H ₈ Cl ₂ N ₂ O ₂ S |
| 3 | -CH ₂ -C ₆ H ₅ | H | 114-115.5 | 67 | EtOH-H ₂ O | I | C ₁₄ H ₁₀ N ₂ O ₂ S |
| 4 | -(CH ₂) ₂ -C ₆ H ₅ | H | 77.5-80 | 58 | 2-PrOH | I | C ₁₅ H ₁₂ N ₂ O ₂ S |
| 5 |  | H | 118-120 | 13 | 2-PrOH | I | C ₁₇ H ₁₈ N ₂ O ₂ S |



^a Analytical results for C, H, and N were within ±0.4% of theoretical values.

Table II. 2-Amino-5-[(aralkyl and alicyclic)thio]benzonitriles

|  | | | | | | | |
|---|--|----|---------|-------------------|--|-----------|--|
| No. | R | Z | Mp, °C | Yield purified, % | Purification solvent | Procedure | Formula ^a |
| 6 | <i>c</i> -C ₆ H ₁₁ | H | 96-99 | 88 | EtOH-H ₂ O | III | C ₁₃ H ₁₆ N ₂ S |
| 7 | -CH ₂ -C ₆ H ₄ - <i>p</i> -Cl | Cl | 151-155 | 67 | EtOH | III | C ₁₄ H ₁₀ Cl ₂ N ₂ S |
| 8 | -CH ₂ -C ₆ H ₅ | H | 94-95 | 68 | EtOH-H ₂ O | III | C ₁₄ H ₁₂ N ₂ S |
| 9 | -CH(CH ₃)-C ₆ H ₄ - <i>p</i> -Cl | H | 89-91 | 19 | C ₆ H ₆ -cyclohexane | III | C ₁₅ H ₁₃ ClN ₂ S |

^a C (for 8): calcd, 69.97; found, 70.39. All other analytical values for C, H, and N were within ±0.4% of theoretical values.

Table III. 2,4-Diamino-6-[(aralkyl and alicyclic)thio]quinazolines

|  | | | | | | | |
|---|---|----|-------------|-------------------|-------------------------|-----------|---|
| No. | R | Z | Mp, °C | Yield purified, % | Purification solvent | Procedure | Formula ^c |
| 10 | <i>c</i> -C ₆ H ₁₁ | H | 190-192 | 71 | EtOH-NH ₄ OH | IV | C ₁₄ H ₁₈ N ₄ S |
| 11 | -CH ₂ -C ₆ H ₄ - <i>p</i> -Cl | Cl | 236-240 | 77 | DMF-H ₂ O | V | C ₁₅ H ₁₂ Cl ₂ N ₄ S |
| 12 | -CH ₂ -C ₆ H ₄ - <i>p</i> -Cl | H | 223-225 | 67 | DMF-aq NaOH | IV | C ₁₅ H ₁₃ ClN ₄ S |
| 13 | -CH ₂ -C ₆ H ₅ | H | 192-193.5 | 70 | EtOH-H ₂ O | IV | C ₁₅ H ₁₄ N ₄ S |
| 14 | -CH(CH ₃)-C ₆ H ₄ - <i>p</i> -Cl | H | 235-236.5 | 45 | EtOH | IV | C ₁₆ H ₁₅ ClN ₄ S |
| 15 | -(CH ₂) ₂ -C ₆ H ₅ | H | 156.5-159.5 | 24 | EtOH | IV | C ₁₆ H ₁₆ N ₄ S·0.33C ₂ H ₆ O·0.5H ₂ O ^{a,b} |
| 16 |  | H | 339-341 dec | 38 | DMF-H ₂ O | IV | C ₁₈ H ₂₂ N ₄ S |

^a The NMR spectrum confirmed the presence of ethanol. ^b H₂O: calcd, 2.80; found, 2.43. ^c N (for 13): calcd, 19.84; found, 20.26. C (for 16): calcd, 66.22; found, 65.80. All other analytical values were within ±0.4% of theoretical values.

5,6-dichloro-2-nitrobenzonitrile (Vb) with the appropriate aralkyl or alicyclic thiopseudourea hydrohalide IV in ethanol, using potassium hydroxide as an acid scavenger, produced the corresponding 2-nitro-5-[(aralkyl or alicyclic)thio]benzonitrile VI (1-5, Table I) in 13-67% yield (procedure I). Both the desired 2-chloro-3-[(*p*-chlorobenzyl)thio]-6-nitrobenzonitrile (2, Table I) (27% yield) and a by-product, 2,3-dichloro-6-[(*p*-chlorobenzyl)thio]benzonitrile (13% yield), were obtained from the reaction of 5,6-dichloro-2-nitrobenzonitrile with 2-(*p*-chlorobenzyl)-2-thiopseudourea hydrochloride (procedure II). Reduction of the nitrobenzonitriles VI with stannous chloride-hydrochloric acid in glacial acetic acid (procedure III) afforded the 2-amino-5-[(aralkyl and alicyclic)thio]-

benzonitriles VII (6-9, Table II) (19-88% yield). Cyclization of the aminobenzonitriles with chloroformamidine hydrochloride⁸ in dry diglyme (procedure IV) or in dimethyl sulfone (procedure V) proceeded in 24-77% yield to give the desired 2,4-diamino-6-[(aralkyl and alicyclic)thio]quinazolines VIII (10-16, Table III). The 2,4-diamino-6-(benzylthio)quinazolines IX (17 and 19, Table IV) were obtained either by oxidation of the 2,4-diamino-6-(benzylthio)quinazolines VIII with 30% hydrogen peroxide in glacial acetic acid (procedure VI) or with the bromine complex of 1,4-diazabicyclo[2.2.2]octane⁹ in 70% aqueous acetic acid (procedure VIII). Oxidation of 2,4-diamino-6-(benzylthio)quinazolines VIII with 30% hydrogen peroxide in glacial acetic acid gave the corre-

Table IV. 2,4-Diamino-6-[(benzyl)sulfinyl- and sulfonyl]quinazolines

| No. | X | Y | Z | Mp, °C | Yield purified, % | Purificn solvent | Procedure | Formula ^b | |
|-----|----|-----------------|----|-------------|-------------------|-----------------------|-----------|--|--|
| 17 | Cl | SO | Cl | 256-258 dec | 55 | DMF-H ₂ O | VI | C ₁₅ H ₁₂ Cl ₂ N ₄ OS | |
| 18 | Cl | SO ₂ | Cl | 274-276 | 42 | DMF-H ₂ O | VII | C ₁₅ H ₁₂ Cl ₂ N ₄ O ₂ S | |
| 19 | Cl | SO ₂ | H | 234-236 | 74 | EtOH | VIII | C ₁₅ H ₁₃ ClN ₄ OS | |
| 20 | Cl | SO ₂ | H | 294-296 | 49 | EtOH | VII | C ₁₅ H ₁₃ ClN ₄ O ₂ S·0.9H ₂ O ^a | |
| 21 | H | SO ₂ | H | 277-280 dec | 18 | EtOH-H ₂ O | VII | C ₁₅ H ₁₄ N ₄ O ₂ S·1.8H ₂ O | |

^a H₂O: calcd, 4.44; found, 4.29. ^b Analytical values for C, H, and N are all within ±0.4% of theoretical values.

Table V. Parenteral Antimalarial Effects of 2,4-Diamino-6-[(aralkyl and alicyclic)thio-, sulfinyl-, and sulfonyl]quinazolines against *Plasmodium berghei* in Mice

| No. | R | Y | Z | ΔMST, C or T ^a after single sc mg/kg dose | | | | | |
|---------------------------|---|-----------------|----|--|----------|---------|----------|----------|-----|
| | | | | 640 | 320 | 160 | 80 | 40 | 20 |
| 10 | c-C ₆ H ₁₁ | S | H | C5 | 13.2; C2 | 9.3 | 5.7 | 2.5 | 0.7 |
| 11 | -CH ₂ -C ₆ H ₄ -p-Cl | S | Cl | 8.1 | 12.9; C2 | 9.1 | 6.1 | 2.7 | 0.7 |
| 12 | -CH ₂ -C ₆ H ₄ -p-Cl | S | H | 7.9 | 3.1 | 1.7 | 1.1 | 0.5 | 0.5 |
| 13 | -CH ₂ -C ₆ H ₅ | S | H | 25.5; C2 | 9.8 | 4.4 | 2.6 | 0.8 | 0.4 |
| 14 | -CH ₂ -C ₆ H ₅ | S | H | 17.3; C3 | 4.9 | 4.2 | 0.9 | 0.8 | 0.5 |
| 15 | -CH(CH ₃)-C ₆ H ₄ -p-Cl | S | H | 10.9 | 17.0; C2 | 10.9 | 9.7 | 5.7 | 3.7 |
| 16 | -(CH ₂) ₂ -C ₆ H ₅ | S | H | 10.7 | 17.8; C2 | 11.2 | 9.6 | 6.0 | 4.0 |
| 17 | | S | H | 2.9 | 17.2; C2 | 4.5 | 0.9 | 0.5 | 0.5 |
| 18 | -CH ₂ -C ₆ H ₄ -p-Cl | SO | Cl | 0.3 | 1.1 | 0.3 | 0.3 | 0.3 | 0.1 |
| 19 | -CH ₂ -C ₆ H ₄ -p-Cl | SO ₂ | Cl | 0.1 | | 0.1 | | 0.1 | |
| 20 | -CH ₂ -C ₆ H ₄ -p-Cl | SO | H | 5.9 | 2.9 | 0.9 | 0.7 | 0.5 | 0.3 |
| Ia·HOAc | -CH ₂ -C ₆ H ₄ -p-Cl | SO ₂ | H | 5.9 | 0.9 | 0.3 | 0.3 | 0.1 | 0.1 |
| II | | | | C5 | C5 | 9.9; C3 | 12.9 | 7.1 | 2.5 |
| | | | | | C5 | 9.9; C3 | 13.1 | 7.3 | 2.7 |
| | | | | 13.3; T3 | 11.2 | 7.7 | 3.7 | 1.7 | 1.3 |
| | | | | | 11.5 | 7.2 | 3.6 | 1.8 | 1.2 |
| Cycloguanil hydrochloride | | | | T5 | C3; T2 | C5 | 21.6; C2 | 13.4; C1 | 7.9 |
| | | | | | C2; T3 | C5 | 21.6; C2 | 13.4; C1 | 8.1 |

^a ΔMST is the mean survival time (days) of treated mice (MSTT) minus the mean survival time (days) of control mice (MSTC). In the present study, the MSTC ranged from 6.1 to 6.2 days. T signifies the number of toxic deaths occurring on days 2-5 after infection which are attributed to drug action. C indicates the number of mice surviving at 60 days postinfection and termed "cured"; data to establish parasitological cure based on subinoculation are unavailable. Each entry at each dose level represents results with a five-animal group.


sponding 2,4-diamino-6-(benzylsulfonyl)quinazoline X (18, 20, and 21, Table IV) in 18-42% yield (procedure VII).

Biology. Suppressive Antimalarial Screening in Mice. The 2,4-diamino-6-[(aralkyl and alicyclic)thio-, sulfinyl-, and sulfonyl]quinazolines (10-20, Table V) were evaluated parenterally against a normal drug-sensitive strain of *P. berghei* in mice.^{10,11} The drugs were dissolved or suspended in sesame or peanut oil and were administered in a single subcutaneous dose 72 h after infection. Antimalarial activity is assumed when the mean survival time of the treated mice is extended. The results, which are summarized in Table V, show that none of the compounds were as active as the acetate salt of 2,4-diamino-6-[(3,4-dichlorobenzyl)amino]quinazoline (Ia).

However, it is interesting to note that certain of the thio compounds, notably 10, 12, 14, and 15, were less toxic and more active than the oxygen bioisostere 2,4-diamino-6-[(p-chlorobenzyl)oxy]quinazoline (II). The presence of a halogen in the 5 position of the quinazoline ring was detrimental to activity in the three cases examined, 11, 17, and 18, in contrast to previous work with the nitrogen analogues related to I. In addition, further oxidation of the sulfur also decreased activity.

Antibacterial Activity. Most of the 2,4-diamino-6-[(aralkyl and alicyclic)thio-, sulfinyl-, and sulfonyl]quinazolines (10, 12, 14, and 16-20) were tested in vitro against the following pathogenic bacteria: *Streptococcus faecalis* (MGH-2), normal (UC-76) and drug-resistant

Table VI. In Vitro Antibacterial Effects of 2,4-Diamino-6-[(aralkyl and alicyclic)thio-, sulfinyl-, and sulfonyl]quinazolines

| No. | R | Y | Z | Min inhibitory concn, $\mu\text{g/mL}$ | | |
|--------------|---|-----------------|----|--|---------------------------|----------------------------|
| | | | | <i>S. faecalis</i> MGH-2 | <i>S. aureus</i> UC-76 | <i>S. aureus</i> S18713 |
| 10 | c-C ₆ H ₁₁ | S | H | 10 | <0.25 | 10 |
| 12 | -CH ₂ -C ₆ H ₄ -p-Cl | S | Cl | <0.25 | <0.25 | <0.25 |
| 14 | -CH(CH ₃)-C ₆ H ₄ -p-Cl | S | H | <0.25 | <0.25 | 1 |
| 16 |  | S | H | <0.25 | <0.25 | <0.25 |
| 17 | -CH ₂ -C ₆ H ₄ -p-Cl | SO | Cl | <0.25 | >25 | >25 |
| 18 | -CH ₂ -C ₆ H ₄ -p-Cl | SO ₂ | Cl | <0.25 | 5 | 10 |
| 19 | -CH ₂ -C ₆ H ₄ -p-Cl | SO | H | >25 | 25 | >25 |
| 20 | -CH ₂ -C ₆ H ₄ -p-Cl | SO ₂ | H | >25 | >25 | >25 |
| Trimethoprim | | | | <0.25 | <0.25 | <0.25 |

(S18713), *Staphylococcus aureus*, *Pseudomonas aeruginosa* (28), *Escherichia coli* (Vogel), and *Shigella sonnei* (C-10). A modification of the gradient plate procedure of Szybalski¹² and Webb and Washington¹³ was used. Although none of the compounds tested showed appreciable activity against *P. aeruginosa* (28), *E. coli* (Vogel), and *S. sonnei* (C-10), many were active against *S. faecalis* (MGH-2) and the *S. aureus* strains. The results of these activities are tabulated in Table VI. Two compounds, 2,4-diamino-6-[(p-chlorobenzyl)thio]quinazoline (12) and 6-(1-adamantylthio)-2,4-diaminoquinazoline (16), inhibited *S. faecalis* MGH-2, *S. aureus* UC-76, and *S. aureus* S18713 at concentrations of <0.25 $\mu\text{g/mL}$. Only 2,4-diamino-6-[(p-chlorobenzyl)sulfonyl]quinazoline (20) was completely inactive.

Conclusion

The thio bioisosteres of the 2,4-diamino-6-(aralkyl-amino)quinazoline antifolates Ia do not provide any advantage when examined for antimalarial activity. Interestingly, they are more active than the corresponding oxygen bioisosteres—an advantage which is lost if the oxidation state of the sulfur is raised to that of sulfoxide or sulfone.

Experimental Section

Melting points (corrected) were taken on a Thomas-Hoover capillary melting point apparatus.

The requisite precursor 5-chloro-2-nitrobenzonitrile (Va) is commercially available¹⁴ and the preparation of 5,6-dichloro-2-nitrobenzonitrile (Vb) is described below. 2-(p-Chlorobenzyl)-2-thiopseudourea hydrobromide was obtained commercially.¹⁵ Treatment¹⁶ of 1-bromoadamantane¹⁴ with thiourea and hydrobromic acid in acetic acid gave 2-(1-adamantyl)-2-thiopseudourea monohydrobromide. The remaining aralkyl and alicyclic thiopseudoureas were obtained by allowing the requisite halide to react with thiourea in acetone.¹⁷

5,6-Dichloro-2-nitrobenzonitrile (Vb). A mixture of 45.3 g (0.20 mol) of 1,2,3-trichloro-4-nitrobenzene¹⁴ and 17.9 g (0.21 mol) of CuCN in 120 mL of N-methyl-2-pyrrolidinone was stirred and heated in an oil bath at 145–150 °C (external temperature) for 6 h. The reaction mixture was allowed to cool to room temperature and was stirred at room temperature for 18 h. The mixture was poured with stirring into 1.6 L of H₂O. Within 15 min, the precipitate had solidified and the crude brown-black solid was collected by filtration, washed thoroughly with H₂O, and air-dried. A second identical run was made, and the combined crude solids were stirred with 1.2 L of boiling EtOH for 45 min and filtered. The filtrate was treated with decolorizing charcoal, the charcoal was removed by filtration, and the filtrate was

concentrated to dryness in vacuo. The residue was crystallized from 400 mL of EtOH to give 51.0 g (59%) of product, mp 75–92 °C, which was of satisfactory purity for use in successive reactions. A sample was recrystallized from EtOH to give an analytical sample, mp 90–93 °C. Anal. (C₇H₃Cl₂N₂O₂) C, H, Cl, N.

2-Nitro-5-[(aralkyl and alicyclic)thio]benzonitriles VI (1–5, Table I). **Procedure I.** To a stirred suspension of 6.0 g (0.0252 mol) of 2-(cyclohexyl)-2-thiopseudourea hydrobromide and 4.6 g (0.025 mol) of 5-chloro-2-nitrobenzonitrile in 70 mL of absolute ethanol was added dropwise a solution of 2.8 g (0.05 mol) of potassium hydroxide in 20 mL of absolute ethanol. The mixture was stirred at room temperature for 2.5 days and then filtered to collect the precipitate. The solid was washed well with water, dried, and recrystallized from cyclohexane to give 2.5 g (38%) of 5-(cyclohexylthio)-2-nitrobenzonitrile (1), mp 84–85 °C.

Procedure II. A solution of 7.2 g (0.13 mol) of potassium hydroxide pellets in 150 mL of ethanol was added dropwise to a stirred solution of 9.6 g (0.044 mol) of 5,6-dichloro-2-nitrobenzonitrile and 12.0 g (0.05 mol) of 2-(p-chlorobenzyl)-2-thiopseudourea hydrochloride in 150 mL of ethanol at 30–38 °C. The mixture was stirred 0.5 h and filtered. The filter cake was washed with water and recrystallized from ethanol to give 4.0 g (27%) of 2-chloro-3-[(p-chlorobenzyl)thio]-6-nitrobenzonitrile (2), mp 145–146 °C.

The filtrate of the reaction mixture afforded a second crop which was recrystallized from ethanol to give 1.8 g (13%) of the by-product 2,3-dichloro-6-[(p-chlorobenzyl)thio]benzonitrile, mp 106–108 °C. Anal. (C₁₄H₉Cl₃NS) C, H, N.

The other requisite 2-nitro-5-[(aralkyl and alicyclic)thio]benzonitriles VI not listed in Table I were prepared in a similar manner. These intermediates were purified and then reduced directly to the corresponding 2-amino-5-[(aralkyl and alicyclic)thio]benzonitriles VII without microanalysis.

2-Amino-5-[(aralkyl and alicyclic)thio]benzonitriles VII (6–9, Table II). **Procedure III.** To a stirred solution of 9.0 g (0.04 mol) of stannous chloride dihydrate in a mixture of 30 mL of concentrated hydrochloric acid and 5 mL of glacial acetic acid was added slowly a warm solution of 3.2 g (0.012 mol) of 5-(cyclohexylthio)-2-nitrobenzonitrile (1) in 23 mL of glacial acetic acid. Before the addition was completed, a white solid began to precipitate. The suspension was stirred at room temperature for 18 h and poured into a stirred ice-water mixture containing 50 mL of 50% sodium hydroxide solution. The white solid which formed was collected and dried. The crude product was dissolved in hot ethanol, filtered to remove some insoluble solid, allowed to cool to room temperature, and poured into water. The solid that formed was collected and dried to give 2.5 g (88%) of 2-amino-5-(cyclohexylthio)benzonitrile (6), mp 96–99 °C.

The other intermediate 2-amino-5-[(aralkyl and alicyclic)thio]benzonitriles VII were not analyzed but were used directly in the cyclization step following crystallization from aqueous ethanol.

2,4-Diamino-6-[(aralkyl and alicyclic)thio]quinazolines VIII (10–16, Table III). Procedure IV. A mixture of 2.3 g (0.01 mol) of 2-amino-5-(cyclohexylthio)benzonitrile (6) and 1.7 g (0.015 mol) of chloroformamidinium hydrochloride⁸ in 5 mL of dry diglyme was stirred and heated in an oil bath at 150 °C (bath temperature) for 0.5 h. During this time hydrogen chloride was evolved, a solution formed, and a new solid precipitated. The mixture was cooled and the solid was collected, washed with ether, and dried. It was recrystallized once from 90% aqueous ethanol containing an excess of ammonium hydroxide and then reprecipitated from 95% ethanol containing 0.5 mL of 2 N sodium hydroxide by addition of water. The pale yellow crystals were collected and dried to give 2.0 g (71%) of 2,4-diamino-6-(cyclohexylthio)quinazoline (10), mp 190–192 °C with preliminary softening.

Procedure V. A mixture of 1.0 g (0.0032 mol) of 6-chloro-5-[(p-chlorobenzyl)thio]anthranilonitrile (7), 0.75 g (0.0065 mol) of chloroformamidinium hydrochloride,⁸ and 4.0 g of dimethyl sulfone was heated for 1 h in an oil bath that had been preheated to 160 °C. The dark solution was poured into water and the resulting cloudy solution was warmed on the steam bath and made basic with 50% sodium hydroxide. The precipitate that formed was collected, washed with water, and recrystallized from *N,N*-dimethylformamide–water to give 0.86 g (77%) of 2,4-diamino-5-chloro-6-[(p-chlorobenzyl)thio]quinazoline (11), mp 236–240 °C.

2,4-Diamino-6-[(benzyl)sulfinyl- and sulfonyl]quinazolines IX and X (17–21, Table IV). Procedure VI. A mixture of 0.64 g (0.0018 mol) of 2,4-diamino-5-chloro-6-[(p-chlorobenzyl)thio]quinazoline (11), 4.4 mL of 30% hydrogen peroxide, and 8 mL of glacial acetic acid was stirred at room temperature for 4 h, and the resulting solution was poured into a mixture of ice and 12 mL of 50% sodium hydroxide. The precipitate that formed was collected, washed with water, and recrystallized from *N,N*-dimethylformamide–water to give 0.37 g (55%) of 2,4-diamino-5-chloro-6-[(p-chlorobenzyl)sulfinyl]quinazoline (17), mp 256–258 °C dec.

Procedure VII. A mixture of 1.0 g (0.0028 mol) of 2,4-diamino-5-chloro-6-[(p-chlorobenzyl)thio]quinazoline (11), 8 mL of 30% hydrogen peroxide, and 15 mL of glacial acetic acid was stirred at room temperature for 48 h, and the resulting solution was poured into a mixture of ice and 23 mL of 50% aqueous sodium hydroxide. The precipitate that formed was collected, washed with water, and combined with 0.41 g of crude product which had been obtained in a similar manner from 0.5 g (0.0014 mol) of starting material. Recrystallization from *N,N*-dimethylformamide–H₂O and drying at 100 °C gave 0.86 g (42%) of 2,4-diamino-5-chloro-6-[(p-chlorobenzyl)sulfonyl]quinazoline (18), mp 274–276 °C.

Procedure VIII. A mixture of 3.2 g (0.01 mol) of 2,4-diamino-6-[(p-chlorobenzyl)thio]quinazoline (12) and 2.3 g (0.0053 mol) of the bromine complex of 1,4-diazabicyclo[2.2.2]octane⁹ in 100 mL of 70% aqueous acetic acid was stirred at room temperature for 18 h. The mixture was poured into a stirred ice–water mixture containing 67 mL of 50% aqueous sodium hydroxide.

The pale yellow solid which precipitated was collected and dried in vacuo. Recrystallization from ethanol followed by drying in vacuo (50 °C) yielded 2.5 g (74%) of 2,4-diamino-6-[(p-chlorobenzyl)sulfinyl]quinazoline (19), mp 234–236 °C. The infrared spectrum displayed sulfoxide absorption at 1040 cm⁻¹.

Acknowledgment. The authors are indebted to Dr. Leo Rane of the University of Miami for the antimalarial testing and to Dr. C. R. Heifetz for the antibacterial testing. We also thank Mr. C. E. Childs and associates for the microanalyses and Dr. J. M. Vandenbelt and co-workers for determination of the spectral data.

References and Notes

- (1) This is communication 40 of a series on antimalarial drugs. For paper 39, which is also the previous paper on folate antagonists, see L. M. Werbel, J. Johnson, E. F. Elslager, and D. F. Worth, *J. Med. Chem.*, **21**, 337 (1978).
- (2) This investigation was supported in part by U.S. Army Medical Research and Development Command Contracts DA-49-193-MD-2754 and DADA-17-72-C-2077. This is Contribution No. 1481 to the Army Research Program on Malaria.
- (3) E. F. Elslager, "New Vistas for Folate Antagonists in the Chemotherapy of Parasitic Infections", J. Maas, Ed., *Proceedings of the 4th International Symposium of Medicinal Chemistry*, Elsevier, Amsterdam, 1974.
- (4) E. F. Elslager, *Drug. Res.*, **18**, 99–172 (1974).
- (5) J. Davoll, J. Clarke, and E. F. Elslager, *J. Med. Chem.*, **15**, 837 (1972).
- (6) P. E. Thompson, A. Bayles, and B. Olszewski, *Exp. Parasitol.*, **25**, 32 (1969).
- (7) E. F. Elslager, J. Clarke, J. Johnson, L. M. Werbel, and J. Davoll, *J. Heterocycl. Chem.*, **9**, 759 (1972).
- (8) A. Hantzsch and A. Vagt, *Justus Liebigs Ann. Chem.*, **314**, 366 (1900).
- (9) S. Oae, Y. Ohnishi, S. Kozuka, and W. Tagaki, *Bull. Chem. Soc. Jpn.*, **39**, 364 (1964).
- (10) The parenteral antimalarial screening was carried out by Dr. Leo Rane of the University of Miami, and test results were supplied through the courtesy of Dr. David P. Jacobus, Dr. T. R. Sweeney, and Dr. E. A. Steck of the Walter Reed Army Institute of Research.
- (11) For a description of the test method, see T. S. Osdene, P. B. Russell, and L. Rane, *J. Med. Chem.*, **10**, 431 (1967).
- (12) W. Szybalski, *Microb. Genet. Bull.*, **5**, 16 (1951).
- (13) A. H. Webb and L. Washington, *Bacteriol. Proc.*, **52** (1966).
- (14) Aldrich Chemical Co., Milwaukee, Wis.
- (15) Eastman Organic Chemicals, Rochester, N.Y.
- (16) British Patent 1 020 058.
- (17) The procedure was similar to that of A. J. Vejdelek et al., *Chem. Listy*, **47**, 49 (1953).

A New Class of Antimalarial Drugs: Derivatives of Benzothiopyrans¹

Raj K. Razdan,*^{2a} Robert J. Bruni, Avinash C. Mehta, Klaus K. Weinhardt, and Zinon B. Papanastassiou^{2b}

Arthur D. Little, Inc., Acorn Park, Cambridge, Massachusetts 02140. Received October 25, 1977

A series of substituted benzothiopyrans was synthesized and examined for antimalarial activity. Some were found to be active and curative at dose levels of 160–360 mg/kg against *Plasmodium berghei* in mice. A few observations concerning structure–activity relationships were made. The benzothiopyrans were prepared by treatment of either the *gem*-dichloro- or the thionothioflavone intermediate with various primary amines. The thionothioflavone intermediates were made from thioflavones. Condensation of thiophenols with benzoyl acetates gave the thioflavones.

We wish to report some derivatives of benzothiopyrans as a new class of antimalarial drugs³ that are active in mice (against *Plasmodium berghei*) and chicks (against *Plasmodium gallinaceum*) in the Rane screen.⁴ Some of these

benzothiopyrans were curative at dose levels of 160–360 mg/kg in mice; a limited study of structure modification, however, did not result in compounds with any greater potency. In the same test, some of the most active known